Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "Shares"

324 News Found

Biocon Biologics Global to raise funds through senior secured notes
News | September 26, 2024

Biocon Biologics Global to raise funds through senior secured notes

The Notes shall not be offered or sold in India


Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides
News | September 06, 2024

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare


Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
News | August 30, 2024

Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split

The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector


Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
News | August 15, 2024

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore


Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
News | August 10, 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.


Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
News | August 02, 2024

Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024


Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
News | July 31, 2024

Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn

Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio


Merck completes acquisition of EyeBio
News | July 16, 2024

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret


Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
News | July 10, 2024

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies